the pharmaceutical industry pay most of next year's bill, while Barbacid hopes that the government will keep its promise. The task was much more challenging to him, he admits, than if he had been offered a similar project in the US. Nevertheless, he does not like to think that he is unique and welcomes the creation of similar institutions -most notably one on cardiovascular diseases led by British-Honduran researcher Salvador Moncada -to create a solid research basis for the Spanish public health system. Some Spanish scientists think that the public money that will go to CNIO will shrink the funds for their own work in oncology but Barbacid says the community is so small that there is no danger of duplicating work: "We have excellent relations with other groups, and I wish there were ten other centres like this in Spain". For the time being, CNIO is unique in Spain, as it will operate as a private enterprise through a foundation and will receive money from the national budget, the Spanish and European research programs and also from the pharmaceutical industry and private donors. Moreover, the researchers work under contracts, they will not be government officials for life as is predominant in the rest of the Spanish public research centres and universities. This in itself is something revolutionary for Spanish science and has created resentment among certain groups.
The CNIO will tackle both basic and 'translational' research in a flexible environment. Its first project will be one of applied science in molecular pathology to develop biochips. The new genetic assays can quickly and automatically analyse individual genomes for use in cancer diagnosis within the national health system. The biochips will indicate the clinical behaviour of the tumour and its reaction to drugs. "It is a priority program which will take from three to five years to get established", says Barbacid. There will also be a drug discovery program in oncology similar to the ones in pharmaceutical companies. "We will not work with patients, we will do the preclinical research and the hospitals will continue the work from there". Finally, there will be basic research on the mechanisms that are involved in the origin of tumours and on cancer genetics, such as the identification of modifier genes, which influence the development of tumours.
"I have been very lucky because I have worked through one of the most fruitful periods in biomedical research on cancer", says Barbacid. "But after my nearly ten years experience in Bristol-Myers Squibb as head of research in oncology, what I would really like to do is to translate this golden age of science into drugs to fight cancer. I think this is the time for an important effort in applied research". One thing the CNIO will not work on, for the time being, is gene therapy. "I have decided to leave it out for the moment", he says.
At the end of its birth process, around 2005, the CNIO will have some 20 groups in basic research: but there is no rush to grow. "Our scientific council has told us not to hurry, to let things develop at their own rhythm".
Malen Ruiz de Elvira is a Spanish science journalist who works for the daily newspaper El Pais.
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Coming home: Mariano Barbacid is setting up a world-class cancer research centre in Madrid after a career developed in the United States.
